HEALTHJun 9 · 13:32 UTCQUARTZColleen Cabili

Tango Therapeutics stock surges on pancreatic cancer drug combo data

Tango Therapeutics' stock surged after a combination of vopimetostat and Revolution Medicines' daraxonrasib showed a 92% response rate in patients with advanced pancreatic cancer.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Tango TherapeuticsorganizationRevolution Medicinesorganizationvopimetostattopicdaraxonrasibtopicpancreatic cancertopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHJun 8 · 11:55 UTC
STAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate
HEALTHJun 4 · 20:18 UTC
What RevMed’s pancreatic cancer drug meant for one patient
HEALTHJun 1 · 02:50 UTC
Daily pill doubles survival time for pancreatic cancer patients
HEALTHJun 4 · 13:18 UTC
Scientists finally crack an “undruggable” pancreatic cancer target and nearly double survival
HEALTHMay 31 · 15:08 UTC
New drug nearly doubles survival rates in some pancreatic cancer patients, study says
HEALTHMay 31 · 12:00 UTC
STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug